Complex takeover battle for iKang healthcare continues

Takeover battle

U.S.-listed iKang ($KANG) remains in play, according to a report, even after an offer earlier this month that suggested a Jack Ma-linked investment firm had won a bidding war for the operator of health clinics in China.

Chinese online news and data service Caixin said China Life Insurance has bid "slightly higher" than $20 per American Depositary Share (ADS), creating another variation on an earlier offer.

Earlier this month, Yufeng, backed by Alibaba ($BABA) founder Ma, announced an all-cash offer of $20-$25 per ADS on its own, beating a management-led bid of $17.80 per ADS made nearly a year ago.

The range of the bid also potentially took it above an offer by Menian Onehealth of $23.50 per ADS late last year and seemed to settle the protracted fight. Menian OneHealth is a rival to iKang in the health clinic business in China.

But according to Caixin, China Life said it remained in the game, even if management has dropped its offer. Earlier this month, iKang founder Zhang Ligang said the protracted battle had damaged operational continuity.

- here's the Caixin story

Related Articles:
Meinian Onehealth sweetens bid for iKang


Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.